John Clement Resigned as Chief Technology and Development Officer and Director at iCo Therapeutics

Date of management change: July 22, 2011 

What Happened?

Vancouver, BC-based iCo Therapeutics has announced the resignation of John Clement as Chief Technology and Development Officer and Director.

 

About the Company

iCo Therapeutics Inc. is a Vancouver-based development company focused on in-licensing drugs with clinical history redosing or reformulating for new or expanded indications. iCo has exclusive worldwide rights to three products. iCo-007, a second generation antisense candidate licensed from Isis Pharmaceuticals, is currently in a Phase I trial in Diabetic Macular Edema patients with compelling early data. iCo-008 is a human monoclonal antibody targeting eotaxin-1 with Phase II clinical history, licensed from AstraZeneca/MedImmune. iCo-009 is a proprietary oral formulation of amphotericin B licensed from the University of British Columbia.

 

About the Person

John Clement previously held various technology roles at iCo Therapeutics

 

Info Source

News

 
 

Other IT executives who recently changed jobs as well: Vargas Sebastian, Hayden Nicholas, Hanson Lena, Moss Craig, Miller Susan, Majmudar Nish, Lane Gordon, Roach Steven, Press Greg, Rients Gary, Stewart Dustin

You can find the full directory of IT executives here.

How would you like to connect with 15,000+ IT executives in charge of $ millions in IT budgets? Find details here.